Quince Therapeutics appoints June Bray to board as independent director
Share
Listen to the news
Quince Therapeutics appoints June Bray to board as independent director
  • Quince Therapeutics expanded board to four directors on April 22, 2026.
  • June Bray was appointed as Class I director, serving until 2026 annual stockholder meeting.
  • Board determined Bray qualifies as an independent director under Nasdaq listing standards.
  • Bray joined board committees covering nominating and governance, audit, compensation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-170572), on April 22, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending